The Satellos team is looking forward to participating in the 30th Annual Congress of the World Muscle Society in Vienna, Oct. 7–11. Don’t miss our scientific poster presentations, including a late-breaking poster on our Phase 1a/b study. Details here: tinyurl.com/2s3n9txx Be sure

Hello from Vienna! The Satellos team is on site at the World Muscle Society 2025 Congress, ready to connect, learn, and share insights on restoring #muscleregeneration in #Duchenne. Be sure to stop by Booth #12 to meet our team and learn more about our work. Don’t miss our

$MSCL News: Today we announced new data demonstrating tolerability and initial exploratory efficacy in the Phase 1b open-label study of SAT-3247 in adults with #Duchenne muscular dystrophy at the World Muscle Society. More in today’s release: tinyurl.com/yrj7v663 #WMS2025

#ICYMI, the Satellos team had a fantastic week at the World Muscle Society Congress (#WMS2025)! From poster sessions to great conversations, it was inspiring to connect with scientists, clinicians, and advocates advancing research across the muscle disease community. Here’s a quick

#SatellosStories: When Marissa Lenger moved from preclinical research into clinical data management, she found what had been missing: the connection to people. “With preclinical research being such an early step in the process of drug development, you rarely witness the

#Duchenne News: Today, Satellos announced that the first patient has been dosed in LT-001, an open-label, long-term follow-up study of SAT-3247 in adult males with Duchenne muscular dystrophy. Full details here: tinyurl.com/satellos-fpd #MuscleRegeneration $MSCL $MSCLF

We’re proud to join this weekend’s Defeat Duchenne Canada Canada Family Forum in Toronto and to introduce the keynote speaker — a reflection of our shared commitment to science, collaboration, and better outcomes for people living with #Duchenne. 🔗 defeatduchenne.ca/news-and-event… $MSCL

Families like Charlie’s remind us what it means to live with #Duchenne — the strength it takes, the hope they hold, and the future they deserve. Read Charlie’s story: satellos.com/charlies-story #MuscleRegeneration #SatellosStories $MSCLF $MSCL (Sound on 🎧)

The Satellos leadership team will participate in healthcare investor conferences next month in Boston and New York. We look forward to the conversations ahead. ir.satellos.com/news/news-deta… #Duchenne #MuscleRegeneration $MSCL $MSCLF

In a recent CheckRare feature, Satellos CMO Dr. Wildon Farwell discusses the science behind SAT-3247 and how restoring the #muscleregeneration process could offer a new therapeutic approach for people living with #Duchenne muscular dystrophy. Watch the interview:

We appreciate the opportunity to speak with Martin Gagel about Satellos’ clinical progress as we work to advance a potential first-in-class treatment for degenerative muscle diseases. 🎬 Watch the full interview below with CEO Frank Gleeson, CMO Dr. Wildon Farwell, and CFO

Thank you to Muscular Dystrophy News Today for highlighting Satellos and our progress toward a potential new treatment approach for #Duchenne muscular dystrophy. Read the full story: 🔗musculardystrophynews.com/news/oral-ther… $MSCL $MSCLF

Satellos has reported its Q3 2025 financial results and announced the appointment of Mark Nawacki to its Board of Directors. Read the full release: tinyurl.com/mscl-Q3-25 #MuscleRegeneration #Duchenne $MSCL $MSCLF